By Dean Seal
Shares of Tevogen Bio surged after the company said it has broadened its relationship with Microsoft in an AI-focused collaboration to develop the biotech's proprietary technology.
The stock was up 52% at $2.06 in premarket trading on Monday. Shares were trading at $7.58 this time a year ago.
The Warren, N.J., company said after the market closed last week that Microsoft is using its AI and cloud capabilities to help build Tevogen's PredicTcell technology, which is designed for predictive precision T-cell targeting.
Microsoft's health and life sciences domain expertise should accelerate Tevogen's target identification and pre-clinical processes, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 27, 2025 06:37 ET (11:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.